SNSS News and Press, Viracta Therapeutics Inc Com From 09/19/19

SOUTH SAN FRANCISCO, Calif., Sept. 19, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Dr. Nicole Onetto, M.D. has been appointed to the Sunesis Board of Directors. Dr. Onetto brings over 20 years of oncology drug development experience to the ...

SOUTH SAN FRANCISCO, Calif., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that Willie Quinn, Chief Financial Officer and Senior Vice President of Finance and Corporate Development, will present at the Wells Fargo Healthcare Conference on Wed...

Sunesis Pharmaceuticals, Inc. (SNSS) Q2 2019 Earnings Conference Call August 07, 2019 04:30 PM ET Company Participants Willie Quinn - Chief Financial Officer & Senior Vice President, Corporate Development Dayton Misfeldt - Interim Chief Executive Officer Judy Fox - Chief Scie...

Sunesis Pharmaceuticals (NASDAQ: SNSS ): Q2 GAAP EPS of -$0.09 beats by $0.01 . More news on: Sunesis Pharmaceuticals, Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, , Read more ...

SOUTH SAN FRANCISCO, Calif., Aug. 07, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today reported financial results for the quarter ended June 30, 2019. Loss from operations for the three and six months ended June 30, 2019 was $6.2 million and $11.9 million. As of J...

SOUTH SAN FRANCISCO, Calif., July 31, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it will host a conference call on Wednesday, August 7 th , 2019 at 4:30 p.m. Eastern Time to discuss corporate updates and financial results for the second quarte...

The NASDAQ Biotechnology Index (INDEXNASDAQ: NBI ) took a steep hit last week, crashing from 3,422.32 points on Monday’s (July 8) open to 3,315.46 points as of 1:32 p.m. EDT on Friday (July 12). A likely catalyst for the index’s crash was US President Donald Trump’s pled...

by Daniel Shvartsman The first half of 2019 saw a lot of green in the markets, as broader indices recovered from the brief bear market in the second half of 2018 and returned to new heights. Despite that, the wall of worry continued to grow, even if the specific concerns changed. Instead o...

Sunesis Pharmaceuticals (NASDAQ: SNSS ) has priced its public offerings of 33,333,667 common shares and 8,333 shares of non-voting Series F Convertible Preferred Stock, at $0.60 and $600 per share, respectively, for combined gross proceeds of ~$25M. Each Series F Share is convertible into ...

SOUTH SAN FRANCISCO, Calif., July 10, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) today announced the pricing of underwritten public offerings of (i) 33,333,667 shares of its common stock and (ii) 8,333 shares of its non-voting Series F Convertible Preferred Stock ...